News

Genmab founder dreams again of IPO of biotech company

After a sudden exit from Y-Mabs Therapeutics, Claus Møller has been quite silent for two years. Now he is building a new biotech company. Claus Møller, who helped found Genmab, has now started a new biotech adventure with Afyx Therapeutics. Claus Møller-San Pedro, who...

AFYX completes financing round of DKK 13.7M

Hørsholm, Denmark, April 15, 2024 After our recent Annual General Meeting the BOD has now in cooperation with the CEO completed an internal financing round to secure the financial basis for the transformation of our company to become an international growth and...

AFYX report from our Annual General Meeting

Hørsholm, Denmark, April 03, 2024 As of August 2023, Dr. Claus Møller-San Pedro took over as the new CEO of Inphena ApS, now a part of AFYX Therapeutics A/S. During an Extraordinary General Meeting in December 2023 our Board of Directors (BOD) was expanded to 3...
Genmab founder dreams again of IPO of biotech company

Genmab founder dreams again of IPO of biotech company

After a sudden exit from Y-Mabs Therapeutics, Claus Møller has been quite silent for two years. Now he is building a new biotech company. Claus Møller, who helped found Genmab, has now started a new biotech adventure with Afyx Therapeutics. Claus Møller-San Pedro, who...

AFYX completes financing round of DKK 13.7M

AFYX completes financing round of DKK 13.7M

Hørsholm, Denmark, April 15, 2024 After our recent Annual General Meeting the BOD has now in cooperation with the CEO completed an internal financing round to secure the financial basis for the transformation of our company to become an international growth and...

AFYX report from our Annual General Meeting

AFYX report from our Annual General Meeting

Hørsholm, Denmark, April 03, 2024 As of August 2023, Dr. Claus Møller-San Pedro took over as the new CEO of Inphena ApS, now a part of AFYX Therapeutics A/S. During an Extraordinary General Meeting in December 2023 our Board of Directors (BOD) was expanded to 3...

Inphena has acquired all shares in AFYX Therapeutics

Inphena has acquired all shares in AFYX Therapeutics

Hørsholm, Denmark, January 09, 2024 Today, we are happy to announce that Inphena A/S has acquired all shares in AFYX Therapeutics A/S. The transaction came in place after the majority shareholders Sofinnova, Novo Holdings and the Lundbeck Foundation decided that the...

OUR LATEST INVESTOR PRESENTATION

Download here:

AFYX Presentation 2024 Investor Non-Confidential

Headquarter

Agern Alle 24
DK-2970 Hørsholm
Denmark

Contact Us

+45 7174 7174
info@afyxtx.com